Market Overview

Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation

Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation

Stemline Therapeutics Inc (NASDAQ: STML) has received FDA approved for Elzonris ahead of the Feb. 21 PDUFA date. The approval coming in two months early highlights “the urgent need” in the indication, according to H.C. Wainwright.

The Analyst

Analyst Raghuram Selvaraju initiated coverage of Stemline Therapeutics with a Buy rating and $38 price target.

The Thesis

The FDA has approved Elzonris infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm, or BPDCN, in adults and in pediatric patients 2 and up, Selvaraju said in the Wednesday initiation note. 

Not only does this represent the first therapy to be approved for BPDCN, it has been approved for treatment-naïve — first-line — patients as well as relapsed or refractory patients who have received intensive chemotherapy, the analyst said. 

It is unlikely that the boxed warning on Elzonris’ prescription label regarding the increased risk of capillary leak syndrome will deter physicians from prescribing BPDCN patients with the drug, since CLS is largely cycle 1-related and manageable with monitoring and pre-emptive measures, as mentioned at the American Society of Hematology 2018 meeting, Selvaraju said.

With Stemline indicating that the planned launch of Elzonris in early 2019 is on track, the probability of success has increased from 90 percent to 100 percent, the analyst said. 

H.C Wainwright increased its annual price estimate for Elzonris from $350,000 to $400,000. 

Price Action

Stemline Therapeutics were trading higher by 5.91 percent at $8.78 at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

FDA Approves First Treatment for Rare Blood Disease

Latest Ratings for STML

Mar 2020Cantor FitzgeraldReiteratesOverweight
Mar 2020JP MorganMaintainsOverweight
Mar 2020Aegis CapitalMaintainsBuy

View More Analyst Ratings for STML
View the Latest Analyst Ratings


Related Articles (STML)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Price Target Initiation FDA Analyst Ratings General Best of Benzinga

Latest Ratings

SAICSunTrust Robinson HumphreyMaintains95.0
GPNSunTrust Robinson HumphreyMaintains165.0
FISVSunTrust Robinson HumphreyMaintains110.0
FISSunTrust Robinson HumphreyUpgrades140.0
WUNorthland SecuritiesMaintains15.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at